Involvement of adenosine receptor agonists on the development of hypersensitivity to acute dose of morphine during morphine withdrawal period

Pharmacological Reports

Volumn 60, Issue 5, 2008, Pages 679-685

  Listos, Joanna ^a   Talarek, Sylwia ^a   Fidecka, Sylwia ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Adenosine receptor agonists; Hypersensitivity; Morphine withdrawal signs

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 N CYCLOPENTYLADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME ACTIVATION; LOCOMOTION; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PROTEIN FUNCTION;

EID: 57849112281     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Acquas E, Di Chiara G: Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem, 1992, 58, 1620-1625.
2. Ahtee L, Attila LM, Carlson KR, Haikala H: Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state. J Pharmacol Exp Ther, 1989, 249, 303-310.
3. Bailey CP, Connor M: Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol, 2005, 5, 60-68.
4. 2A receptor heteromers. J Neurosci, 2006, 26, 2080-2087.
5. 2 receptors in rat striatal membranes. Proc Natl Acad Sci, 1991, 88, 7238-7241.
6. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev, 2001, 53, 527-552.
7. Hack SP, Vaughan CW, Christie MJ: Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro. Neuropharmacology, 2003, 45, 575-584.
8. Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL, Downs DA: Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology, 1989, 98, 31-37.
9. 2A receptors in the alcohol withdrawal syndrom. Alcohol, 1999, 19, 157-162.
10. 1 receptors in morphine dependence. Brain Res, 1994, 657, 347-350.
11. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C: Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self administration. Pharmacol Biochem Behav, 2001, 68, 797-803.
12. Koob GF: Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol, 2003, 13, 442-452.
13. Koob GF, Heinrichs SC: A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res, 1999, 848, 141-152.
14. Kotlińiska J, Bocheński M: Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. Eur J Pharmacol, 2007, 558, 113-118.
15. Le Moal M, Simon H: Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev, 1991, 71, 155-234.
16. Listos J, Malec D, Fidecka S: Adenosine receptor antagonists intensify the benzodiazepine withdrawal signs in mice. Pharmacol Rep, 2006, 58, 643-651.
17. Listos J, Talarek S, Fidecka S: Adenosine receptor agonists attenuate the development of diazepam withdrawal-induced sensitization in mice. Eur J Pharmacol, 2008, 588, 72-77.
18. Lu L, Liu D, Ceng X, Ma L: Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci, 2000, 12, 4398-4404.
19. Macey DJ, Koob GF, Markou A: CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res, 2000, 866, 82-91.
20. Milanés MV, Laorden ML, Chapleur-Château M, Burlet A: Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J Pharmacol Exp Ther, 1998, 285, 700-706.
21. Noda Y, Nabeshima T: Opiate physical dependence and N-methyl~D-aspartate receptors. Eur J Pharmacol, 2004, 500, 121-128.
22. 2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur J Pharmacol, 1999, 375, 101-113.
23. Robinson TE, Berridge KC: The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction, 2000, 95, 91-117.
24. 2A receptors and basal ganglia physiology. Prog Neurobiol, 2007, 83, 277-292.
25. Shaham Y, Erb S, Leung S, Buczek Y, Stewart J: CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology, 1998, 137, 184-190.
26. Spanagel R, Weiss F: The dopamine hypothesis of reward: past and current status. Trends Neurosci, 1999, 22, 521-527.
27. Vanderschuren LJ, Kalivas PW: Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology, 2000, 151, 99-120.
28. Zarrindast MR, Gholami A, Sahraei H, Haeri-Rohani A: Role of nitric oxide in the acquisition and expression of apomorphine- or morphine-induced locomotor sensitization. Eur J Pharmacol, 2003, 482, 205-213.